WO2006069656A1 - Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation - Google Patents

Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation Download PDF

Info

Publication number
WO2006069656A1
WO2006069656A1 PCT/EP2005/013624 EP2005013624W WO2006069656A1 WO 2006069656 A1 WO2006069656 A1 WO 2006069656A1 EP 2005013624 W EP2005013624 W EP 2005013624W WO 2006069656 A1 WO2006069656 A1 WO 2006069656A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbonyl
amino
naphthalene
methyl
ylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/013624
Other languages
English (en)
French (fr)
Inventor
Stephanie Knieps
Juergen Dedio
Holger Heitsch
Werngard Czechtizky
Sven Grueneberg
Stephen Shimshock
Raymond W. Kosley
Carolina Lanter
Hui Li
Rosy Sher
Aleksandra Weichsel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT05818685T priority Critical patent/ATE543795T1/de
Priority to BRPI0519452-0A priority patent/BRPI0519452A2/pt
Priority to NZ556192A priority patent/NZ556192A/en
Priority to JP2007548720A priority patent/JP5123667B2/ja
Priority to MX2007007068A priority patent/MX2007007068A/es
Priority to CA002592430A priority patent/CA2592430A1/en
Priority to AU2005321609A priority patent/AU2005321609B2/en
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to EP05818685A priority patent/EP1836158B1/en
Publication of WO2006069656A1 publication Critical patent/WO2006069656A1/en
Priority to IL184173A priority patent/IL184173A/en
Priority to US11/771,958 priority patent/US7919628B2/en
Anticipated expiration legal-status Critical
Priority to NO20073932A priority patent/NO20073932L/no
Priority to US13/079,522 priority patent/US8283479B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • Chemokines are a family of low molecular weight proteins (8-13 kDa) that are classified into four distinct groups depending on the positioning of the cysteine motif at the amino terminus.
  • the family members comprise CXC, CC, XC, and CX3C chemokines of which CXC and CC are the largest and most characterized.
  • the CXC chemokines include interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2), growth-related oncogenes GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , epithelial cell-derived neutrophil activating factor-78 (ENA-78), granulocyte chemoattractant protein-2 (GCP-2), ⁇ - interferon-inducible protein-10 ( ⁇ lP-10), interferon-inducible T cell ⁇ -chemoattractant (I- TAC), monokine induced by ⁇ -interferon (Mig) and platelet factor-4 (PF-4).
  • IL-8 interleukin-8
  • NAP-2 neutrophil-activating protein-2
  • ENA-78 epithelial cell-derived neutrophil activating factor-78
  • GCP-2 granulocyte chemoattractant protein-2
  • ⁇ lP-10 ⁇ - interferon-inducible protein-10
  • I- TAC interferon-inducible T cell ⁇ -chem
  • CC chemokines include RANTES (regulated on activation normal T cell expressed and secreted), macrophage inflammatory proteins MIP-1 ⁇ , MIP-1 ⁇ , monocyte chemoattractant proteins MCP-1 , MCP-2, MCP-3 and eotaxin.
  • the XC family comprises two members, lymphotactin- ⁇ and lymphotactin- ⁇ , and the CX3C family consists only of a single chemokine named fractalkine (Murphy et al., Pharmacol. Rev. 52: 145-176, 2000).
  • Chemokines mediate their biological effects by binding to cell surface molecules, which belong to the superfamily of seven-transmembrane spanning receptors that signal through coupling to heterotrimeric G proteins. Although most chemokine receptors recognize more than one chemokine, they are almost always restricted to a single subclass. Chemokine receptor binding initiates a cascade of intracellular events of which the first step is the binding of the receptor by its high-affinity ligand. This induces a conformational change leading to a dissociation of the receptor-associated heterotrimeric G proteins into ⁇ and ⁇ subunits.
  • G protein subunits are able to activate various effector proteins, including phospholipases leading to generation of inositol trisphosphate, an increase in cytosolic calcium, and activation of protein kinases.
  • This cascade of intracellular events mediates a wide range of functions in different leukocytes such as chemotaxis, degranulation, oxidative burst, phagocytosis, and lipid mediator synthesis.
  • IL-8 lnterleukin-8
  • IL-8 is a key mediator of immunological reactions in inflammatory disorders such as atherosclerosis, ischemia/reperfusion injury, rheumatoid arthritis, chronic obstructive pulmonary disease, respiratory distress syndrome, asthma, cystic fibrosis, and psoriasis (Bizarri et al., Curr. Med. Chem. 2: 67-79, 2003).
  • IL-8 is the most characterized member of the CXC subfamily of chemokines. Leukocyte responses to IL-8 are mediated via specific cell surface receptors, CXCR1 and CXCR2.
  • CXCR2 responds to several additional chemokines including growth-related oncogenes GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , neutrophil- activating protein-2 (NAP-2), epithelial cell-derived neutrophil activating factor-78 (ENA-78), and granulocyte chemoattractant protein-2 (GCP-2).
  • the common denominator shared by all chemokines that activate CXCR2 is a Glu-Leu-Arg (ELR) sequence in the amino terminus, which appears to serve as a recognition sequence for receptor binding and activation (Herbert et al., J. Biol. Chem. 266: 18989-18994, 1991).
  • CXCR1 and CXCR2 are thought to be important in several acute neutrophil-mediated diseases such as acute respiratory distress syndrome and ischemia/reperfusion injuries, as well as in chronic diseases such as asthma, psoriasis, dermatitis, and arthritis.
  • CXCR2 is also expressed by monocytes.
  • monocyte chemotaxis assay this factor induces calcium flux and respiratory burst in monocytes and enhances adhesion of monocytes in static assays.
  • GRO- ⁇ enhances adhesion of monocytes to stimulated endothelial cells.
  • IL-8 is able to induce firm arrest of monocytes on endothelial cells under conditions of physiological flow (Gerszten et al., Nature 398: 718-723, 1999).
  • CXCR2 is strongly expressed on monocytes and macrophages in atherosclerotic lesions where it is suggested to play a key role in chemoattraction, retension, expansion, and activation of monocytes and macrophages, this strongly suggests that CXCR2 and one or more of its ligands (IL-8, GRO- ⁇ ) play a pathophysiological role in atherosclerosis (Huo et al., J. Clin. Invest. 108: 1307-1314, 2001).
  • IL-8 receptors Apart from neutrophils and monocytes, numerous cell types have been shown to express IL-8 receptors. These cell types include neurons, various cancer cells, keratinocytes, and endothelial cells. Several lines of evidence indicate that IL-8 plays a direct role in angiogenesis via stimulation of CXCR2 expressed on endothelial cells. IL- 8 has been shown to bind specifically to endothelial cells and induce chemotaxis. IL-8 is able to induce neovascularization in the absence of inflammatory responses (Koche et al., Science 258: 1798-1801 , 1992).
  • IL-8 could play a key role in melanoma progression and metastasis as patients with melanoma metastases have elevated serum levels of IL-8.
  • IL-8 is supposed to act as an autocrine growth and metastatic factor for melanoma cells (Schadendorf et al., J. Immunol: 151-157, 1993).
  • chemokine receptors CXCR1 and CXCR2 Due to the wide range of actions of IL-8, such as attraction and activation of neutrophils and monocytes/macrophages as well as promotion of endothelial cell proliferation and cancer cell growth, the inhibition of chemokine receptors CXCR1 and CXCR2 is expected to be beneficial in the prevention and treatment of numerous diseases.
  • chemokine such as, but not limited to IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , NAP-2, ENA-78, or GCP-2
  • chemokine such as, but not limited to IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , NAP-2, ENA-78, or GCP-2
  • mediated diseases include adult respiratory distress syndrome, inflammatory bowel disease, ulcerative colitis, Crohn's disease, atopic dermatitis, cystic fibrosis, psoriasis, multiple sclerosis, angiogenesis, restenosis, osteoarthritis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, glomerulonephritis, thrombosis, graft vs. host reaction, allograft rejections, alzheimers disease, malaria, viral infections, traumatic brain injury, pulmonary fibrosis, and cancer.
  • the invention provides novel compounds represented by the formula I and pharmaceutically acceptable salts, solvates, isomers or prodrugs therof, which are inhibitors of chemokine receptors, in particular of CXC-chemokine receptors, more particular of CXCR2, and therefore useful for the prevention and treatment of chemokine mediated diseases.
  • the invention relates to a compound of formula I
  • R3, R4, R5 and R6 are, independently of one another, hydrogen, F, Cl, Br, I, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, cycloalkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 hydrogen atoms may be substituted by fluorine atoms, alkoxy having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, -S-alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1
  • R7 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or C(O)R35;
  • R35 is hydrogen, alkyl with 1 , 2, 3 or 4 carbon atoms or aryl;
  • Y1 , Y2, Y3 and Y4 are, independently of one another, -CR8- or Nitrogen, with the proviso that at least two of Y1 , Y2, Y3 and Y4 are defined as -CR8-;
  • R8 is hydrogen, F, Cl, Br, I, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, cycloalkyl having 1 ,
  • R36 is hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms
  • R37 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms, aryl, C(O)H, C(O)alkyl with alkyl having 1 , 2, 3 or 4 carbon atoms or C(O)aryl
  • R38 is hydrogen, OH, alkyl with 1 ,2,3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl
  • R39, R40, R42 and R43 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl
  • R41 is OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl
  • q and r are, independently of one another, 1 or 2; is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, heterocycle,
  • hydrogen atoms may be substituted by fluorine atoms, -NR9R10, C(O)R44, C(O)N45R46, S(O) S R47, S(O) t NR48R49, -(CH 2 )k-aryl or - (CH2)
  • R9 is hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms
  • R10 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms, aryl
  • R44 is hydrogen, OH, alkyl with 1 ,2,3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms or aryl;
  • R45, R46, R48 and R49 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R47 is OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl; a is zero or 1 ; b, c, k and I are, independently of one another, zero, 1 , 2 or 3; s and t are, independently of one another, 1 or 2; in which the aryl or heteroaryl radical can be condensed to an cycloalkyl or heterocycle radical and in which the aryl or heteroaryl radical and the optionally condensed cycloalkyl or heterocycle radical are unsubstituted or substituted by 1 , 2, 3 or 4 radicals selected from the group consisting of F, Cl, Br, I, OH, CN 1 NO2, SF5, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, cycloalky
  • -heteroaryl in which the aryl and heteroaryl radicals can be substituted by F, Cl, Br, I, alkoxy having 1 , 2, 3 or 4 carbon atoms, alkyl having 1 , 2, 3 or 4 carbon atoms or O a -(CH2)tr(CF2) c -CF3 ;
  • R9 is hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms
  • R10 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms, aryl, C(O)H, C(O)alkyl having 1 , 2, 3 or 4 carbon atoms or C(O)aryl
  • R44 is hydrogen, OH, alkyl with 1 ,2,3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms or aryl
  • R45, R46, R48 and R49 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R47 is OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 ,
  • a is zero or 1 ;
  • b, c, k and I are, independently of one another, zero, 1 , 2 or 3;
  • s and t are, independently of one another, 1 or 2;
  • R11 , R12, R13, R14, R15, R16, R17, R18, R19, R20, R50, R51, R52, R53, R54, R55, R56 and R57 are, independently of one another, hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms, in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 hydrogen atoms may be substituted by fluorine atoms;
  • R21 and R22 are, independently of one another, hydrogen, -SO2-alkyl having 1 , 2, 3 or 4 carbon atoms, -S ⁇ 2-aryl, -C(O)-alkyl with alkyl having 1 ,
  • R23 is alkyl having 1 ,2,3 or 4 carbon atoms or aryl
  • R24 and R25 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R58 is hydrogen, OH, CN, alkyl having 1 , 2, 3 or 4 carbon atoms or alkoxy having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R1 and R2 are, independently of one another, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms; in which the alkyl radicals are unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of F, Cl, Br, I, -SH, -S-alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)OH, -C(O)NH2, NH2,
  • R26 is hydrogen, aryl or heteroaryl, in which the aryl or heteroaryl radical is unsubstituted or substituted by F, Cl,
  • R1 and R2 form, together with the carbon atom to which they are attached, a 3-, 4-, 5- or 6- membered carbon ring, in which the formed carbon ring can be condensed to an aryl or heteroaryl radical; wherein the formed carbon ring and the condensed aryl or heteroaryl radical can be unsubstituted or substituted by 1 , 2 or 3 radicals selected form the group consisting of F, Cl, Br, I or alkyl having 1 , 2, 3 or 4 carbon atoms; and/or a pharmaceutically acceptable salt and/or a prodrug thereof.
  • R3, R4, R5 and R6 are, independently of one another, hydrogen, F, Cl, Br, I, alkyl having 1 , 2, 3 or 4 carbon atoms or alkoxy having 1 , 2, 3 or 4 carbon atoms;
  • R7 is hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms; Y1. Y2, Y3 and Y4 are, independently of one another, -CR8- or Nitrogen, with the proviso that at least two of Y1 , Y2, Y3 and Y4 are defined as -CR8-;
  • R8 is hydrogen, F, Cl, Br, I or alkyl having 1 , 2, 3 or 4 carbon atoms;
  • A is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, heterocycle, aryl or heteroaryl; in which the cycloalkyl or heterocycle radical can be condensed to an aryl radical and in which the cycloalkyl or heterocycle radical is unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of F, Cl, Br, I or alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)-alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)-cycloalkyl having 3, 4, 5 or 6 carbon atoms or -C(O)O-alkyl having 1 , 2, 3 or 4 carbon atoms; in which the aryl or heteroaryl radical can be condensed to an cycloalkyl or heterocycle radical and in which the
  • R9 and R10 are, independently of one another, hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms; a, d and e are, independently of one another, zero or 1 ; b, c, g, h, k and I are, independently of one another, zero, 1, 2 or 3; f is zero, 1 or 2;
  • B is -O-(CR11 R12)-, -C ⁇ C-, -C(R13R14)-C(R15R16)-, -NR17-C(R18R19)- or -NR20-C(O)-;
  • R11 , R12, R13, R14, R15, R16, R17, R18, R19 and R20 are, independently of one another, hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms;
  • D is C(O)OH, C(O)NHR21 or C(N-OH)NHR22;
  • R21 and R22 are, independently of one another, hydrogen, -SO2-alkyl having 1 ,
  • R23 is alkyl having 1 ,2,3 or 4 carbon atoms or aryl
  • R24 and R25 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl
  • R1 and R2 are, independently of one another, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms; in which the alkyl radicals are unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of F, Cl, Br, I, -S-alkyl having, 1 , 2, 3 or 4 carbon atoms or -O m -(CH2) n -R26; m is zero or 1 ; n is zero, 1 , 2 or 3;
  • R26 is hydrogen, aryl or heteroaryl, in which the aryl or heteroaryl radical is unsubstituted or substituted by F, Cl, Br, I, OH or alkyl having 1 , 2, 3 or 4 carbon atoms; or R1 and R2 form, together with the carbon atom to which they are attached, a 3-, 4-, 5- or 6- membered carbon ring; and/or a pharmaceutically acceptable salt and/or a prodrug thereof.
  • R8 is hydrogen, F or Cl;
  • A is cyclohexyl, piperidyl, phenyl, naphthyl, indanyl, 2,3-dihydro- benzo[1 ,4]dioxanyl, benzo[1 ,3]dioxolyl, furyl, thienyl, pyridyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxadiazolyl, triazolyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzoxadiazolyl, benzotriazolyl, benzo-1 ,1-dioxid-thiophenyl or quinolyl; in which cyclohexyl is unsubstituted or substituted by 1
  • SF5 -N(CH 3 )2, methoxy, ethoxy, alkyl having 1 , 2, 3 or 4 carbon atoms, CF 3 , OCF 3 , OCH 2 CF 3 , OCHF 2 , SCH 3 , SOCH 3 , SO 2 CH 3 , SCF 3 , phenyl, benzyl, pyrazolyl, pyrrolyl and triazolyl, in which phenyl can be substituted by Cl;
  • B is -O-C(R11 R12)-; -C ⁇ C-, -C(RISRH)-C(RISRIeK -NRIy-C(RIeRIQ)- Or -NR20-C(O)-;
  • R11 , R13, R14, R15, R16, R18 and R19 are hydrogen;
  • R12, R17 and R20 are hydrogen or methyl;
  • D is C(O)OH, C(O)NHR21 or C(N-OH)NHR22, R21 is -SO2-alkyl having 1 , 2, 3 or 4 carbon atoms or -SO2-phenyl;
  • R22 is hydrogen
  • R1 and R2 are, independently of one another, alkyl having 1 , 2 or 3 carbon atoms; or R1 and R2 form, together with the carbon atom to which they are attached, a 3-, A-, or 5- membered carbon ring; and/or a pharmaceutically acceptable salt and/or prodrug thereof.
  • R8 is hydrogen, F or Cl;
  • A is cyclohexyl, piperidyl, phenyl, naphthyl, indanyl, 2,3-dihydro- benzo[1 ,4]dioxanyl, benzo[1 ,3]dioxolyl, furyl, thienyl, pyridyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxadiazolyl, triazolyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzoxadiazolyl, benzotriazolyl, benzo-1 ,1-dioxid-thiophenyl or quinolyl; in which cyclohexyl is unsubstituted or substituted by 1
  • SF5 -N(CH3)2, methoxy, ethoxy, alkyl having 1 , 2, 3 or 4 carbon atoms, CF 3 , OCF 3 , OCH 2 CF 3 , OCHF 2 , SCH 3 , SOCH 3 , SO 2 CH 3 , SCF 3 , phenyl, benzyl, pyrazolyl, pyrrolyl and triazolyl, in which phenyl can be substituted by Cl;
  • B is -O-C(R11 R12)-;
  • R11 is hydrogen; R12 is hydrogen or methyl; D Js C(O)OH; R1 and R2 are, independently of one another, alkyl having 1 , 2 or 3 carbon atoms; or
  • R1 and R2 form, together with the carbon atom to which they are attached, a 3-, A-, or 5- membered carbon ring; and/or a pharmaceutically acceptable salt and/or a prodrug thereof.
  • Linker X is attached with its left hand side to the carbon atom in the six-membered ring and with its right hand side to the other carbon atom.
  • Y1 , Y2, Y3 and Y4 in compounds of formula I are, independently of one another, described by -CR8- or Nitrogen, with the proviso that at least two of Y1 , Y2, Y3 and Y4 are defined as -CR8-, wherein R8 is hydrogen, F, Cl, Br, I or alkyl having 1 , 2, 3 or 4 carbon atoms; preferably at least three of Y1 , Y2, Y3 and Y4 are defined as -CR8, wherein R8 is hydrogen, F, Cl, Br, I or alkyl having 1 , 2, 3 or 4 carbon atoms, preferably hydrogen or Cl, for example hydrogen; for example Y1 , Y2 and Y3 are CH and Y4 is N or Y1 , Y2, Y3 and Y4 are
  • a in compounds of formula I is described by cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, heterocycle, aryl or heteroaryl, wherein the cycloalkyl or heterocycle radical can be condensed to an aryl radical and wherein the cycloalkyl or heterocycle radical is unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of F, Cl, Br, I, alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)-alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)-cycloalkyl having 3, 4, 5 or 6 carbon atoms or -C(O)O-alkyl having 1 , 2, 3 or 4 carbon atoms and wherein the aryl or heteroaryl radical can be condensed to an cycloalkyl or heterocycle radical and wherein the aryl or heteroaryl radical is unsubstituted or substituted by 1 , 2 or 3
  • aryl or heteroaryl radical is unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of F, Cl, Br, CN, NO2, SFs, -N(CH3)2, methoxy, ethoxy, alkyl having
  • 2,3-Dihydro-benzo[1,4]dioxanyl is unsubstituted
  • cyclohexyl is unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of alkyl having 1 , 2, 3 or 4 carbon atoms, in particular methyl
  • piperidyl is unsubstituted or substituted by alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)CH3, -C(O)CH2CH3, -
  • aryl or heteroaryl radical is unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of F, Cl, Br, CN, NO2, SF5, -N(CH3)2, methoxy, ethoxy, alkyl having 1 , 2, 3 or 4 carbon atoms, CF3, OCF3, OCH2CF3, OCHF 2 , SCH3, SOCH3, SO2CH3, SCF3, phenyl, benzyl, pyrazolyl, pyrrolyl and triazolyl, wherein phenyl can be substituted by
  • 2,3-Dihydro-benzo[1 ,4]dioxanyl is unsubstituted
  • cyclohexyl is unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of alkyl having 1 , 2, 3 or 4 carbon atoms, in particular methyl
  • piperidyl is unsubstituted or substituted by alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)CH3, -C(O)CH2CH3, - C(O)-cyclopropyl, -C(O)CF3, -C(O)OC(CH3)3,
  • the aryl or heteroaryl radical is unsubstituted or substituted by 1, 2 or 3 radicals selected from the group consisting of F, Cl, Br, CN, NO2, SF5, -N(CH3)2, methoxy, ethoxy, alkyl having 1 , 2, 3 or 4 carbon atoms, CF 3
  • a in compounds of formula I is described by unsubstituted cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, heterocycle, aryl or heteroaryl, in which the cycloalkyl or heterocycle radical can be condensed to an aryl radical and in which the aryl or heteroaryl radical can be condensed to an cycloalkyl or heterocycle radical.
  • a in compounds of formula I is described by cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, heterocycle, aryl or heteroaryl, wherein the cycloalkyl or heterocycle radical can be condensed to an aryl radical and wherein the cycloalkyl or heterocycle radical is substituted by 1 , 2 or 3 radicals and wherein the aryl or heteroaryl radical can be condensed to an cycloalkyl or heterocycle radical and wherein the aryl or heteroaryl radical is unsubstituted or substituted by 1 , 2, 3 or 4 radicals; preference is given to compounds of the formula I in which A is described by a monocyclic ring compound, for example a monocyclic cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, heterocycle, aryl or heteroaryl, which is at least substituted once in a position not near to the binding site of the cycloalkyl, heterocycle, aryl or heteroaryl to the linker
  • Linker B is attached with its left hand side to the ring system and with its right hand side to the residue A.
  • D in compounds of formula I is described by C(O)OH, C(O)NHR21 or C(N-OH)NHR22, wherein R21 and R22 are, independent of one another, hydrogen, -SO2-alkyl having 1 , 2, 3 or 4 carbon atoms or -SO2-aryl, -C(O)- alkyl having 1 , 2, 3 or 4 carbon atoms, -C(O)-aryl, -C(O)OR23, -C(O)NR24R25 or CN, wherein R23 is alkyl having 1 , 2, 3 or 4 carbon atoms or aryl and R24 and R25 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl; preference is given to compounds wherein D is C(O)OH, C(O)NHR21 or C(N- OH)NHR22, wherein R22 is hydrogen and R21 is hydrogen, -SO2-alkyl having 1 , 2, 3
  • R1 and R2 are, independently of one another, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which the alkyl radicals are unsubstituted or substituted by 1 , 2 or 3 radicals selected from the group consisting of F, Cl, Br, I, -S-alkyl having, 1 , 2, 3 or 4 carbon atoms or -O m -(CH2) n -R26, wherein m is zero or 1 , n is zero, 1 , 2 or 3 and R26 is hydrogen, aryl or heteroaryl, in which the aryl or heteroaryl radicals are unsubstituted or substituted by F, Cl, Br, I, OH or alkyl having 1 , 2, 3 or 4 carbon atoms, or R1 and R2 form, together with the carbon atom to which they are attached, a 3-, 4-, 5- or 6-membered carbon ring; preference is given to compounds of formula I in which R1 is alkyl having 1 , 2, 3, 4,
  • R2 is alkyl having 1 , 2, 3 or 4 carbon atoms or where R1 and
  • R2 form, together with the carbon atom to which they are attached, a 3-, A-, or 5- membered carbon ring.
  • the compounds of the formula I can be present in the form of their salts.
  • An overview of pharmaceutically employed salts can be found in the "Handbook of Pharmaceutical Salts", edited by P. Heinrich Stahl, Camille G. Wermuth, Verlag Helvetica Chimica Acta, Switzerland, 2002.
  • Suitable base addition salts are salts of all pharmacologically acceptable bases, for example alkali metal, earth alkali metal or metal salts, preferably sodium, potassium, magnesium, calcium or zink salts, or as ammonium salts, for example as salts with ammonia or organic amines or amino acids, preferably as salts formed with ammonia, arginine, benethamine, benzathine, choline, deanol, diethanolamine, ditehylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylendiamine, N-methyl-glucamine, hydrabamine, 1 H-imidazole, lysine, 4-(2-hydroxyethyl)- morpholine, piperazine, 1-(2-hydroxyethyl)-pyrrolidine, triethanolamine or tromethamine; If the compounds contain a basic group, they are capable of forming salts with acid, for example halides, in particular hydrochlorides, hydro
  • This group also corresponds to the physiologically acceptable anions; but also trifluoroacetates. They can also be present as zwitterions. If the inventive compounds contain one or more centers of asymmetry, these may independently of one another have the S and the R configuration.
  • the compounds may be in the form of optical isomers, of diastereomers, of racemates or of mixtures thereof in any ratio.
  • the compounds of the formula I according to the invention can contain mobile hydrogen atoms, that is be present in various tautomeric forms.
  • the present invention relates to all the tautomers of the compounds of the formula I.
  • the present invention furthermore encompasses derivatives of compounds of the formula I, for example solvates, such as hydrates and adducts with alcohols, esters, prodrugs and other physiologically tolerated derivatives of compounds of the formula I, and also active metabolites of compounds of the formula I. Further the invention contains all crystal modifications of compounds of formula I.
  • the invention relates, in particular, to prodrugs of the compounds of the formula I which are not necessarily pharmacologically active in vitro but which are converted in vivo, under physiological conditions, into active compounds of the formula I, for example by hydrolysis in blood.
  • suitable prodrugs for the compounds of the formula I that is chemically modified derivatives of the compounds of the formula I possessing properties which have been improved in a desired manner. Further details with regard to prodrugs can be found, for example, in Fleisher et al., Advanced Drug Delivery Reviews 19 (1996) 115-130; Design of Prodrugs, H. Bundgaard, Ed., Elsevier, 1985; or H. Bundgaard, Drugs of the Future 16 (1991 ) 443.
  • Prodrugs which are especially suitable for the compounds of the formula I are ester prodrugs of carboxylic acid groups, amide prodrugs of carboxylic acid groups and alcohol prodrugs of carboxylic acid groups as well as acyl prodrugs and carbamate prodrugs of acylatable nitrogen-containing groups such as amino groups, amidino groups and guanidino groups.
  • acyl prodrugs or carbamate prodrugs a hydrogen atom which is located on a nitrogen atom is replaced with an acyl group or carbamate group.
  • Suitable acyl groups and carbamate groups for the acyl prodrugs and carbamate prodrugs are, for example, the group D.
  • ester prodrugs and amide prodrugs which may be mentioned are (C-
  • the methyl and ethyl esters of the compounds listed above are included.
  • Alkyl radicals may be straight-chain or branched. This also applies if they carry substituents or occur as substituents of other radicals, for example in alkylamino, alkoxy, arylalkyl, heteroarylalkyl, fluoroalkyl or -SOf-alkyl radicals.
  • Preferred alkyl radicals are methyl, ethyl, n-propyl, isopropyl, tert-butyl and isobutyl.
  • One or more, for example 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13, hydrogen atoms in alkyl radicals may be replaced by fluorine atoms to form fluoroalkyl radicals.
  • Examples of such radicals are difluoromethyl, trifluoromethyl, pentafluoroethyl, 2,2,2- trifluoroethyl; 3,3,3-trifluoropropyl; 3,3,3-trifluorobutyl, 4,4,4-trifluorbutyl.
  • cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, in particular cyclopentyl or cylcohexyl.
  • Cycloalkyl radicals can be saturated or partly unsaturated, especially when they are condensed to an aryl or heteroaryl radical.
  • a cycloalkyl radicals may contain zero, one or two double bonds. This also applies if they carry substituents or occur as substituents of other radicals, for example in the radicyl cycloalkylalkyl.
  • cycloalkyl radicals may be replaced by fluorine atoms to form fluorocycloalkyl radicals.
  • Substituted cycloalkyl radicals may be substituted in identical or different positions.
  • Heterocycle radicals are monocyclic or bicyclic saturated or partly unsaturated 5, 6, 7, 8, 9 or 10-membered ring compounds in which one or more ring atoms are oxygen atoms, sulfur atoms or nitrogen atoms, e.g. 1 , 2 or 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms or a combination of various heteroatoms, in particular two oxygen atoms.
  • Heterocycle radicals includes heterocycloalkyls and heterocycloalkenyls and, therefore, they can be saturated or partly unsaturated, especially when they are condensed to an aryl or heteroaryl radical, for example to form 2,3-Dihydro-benzo[1 ,4]dioxine.
  • heterocycle radicals may contain zero, one or two double bonds.
  • the heterocycle radicals may be attached by all positions, for example by the 1 position, 2 position, 3 position, 4 position, 5 position, 6 position, 7 position or 8 position.
  • Heterocycle radicals may be unsubstituted or be substituted one or more times, for example once, twice or three times, by identical or different radicals in identical or different positions. This applies likewise to heterocycle radicals such as, for example, in the radical heterocycloalkyl.
  • heterocycles are oxirane, aziridine, tetrahydrofurane, tetrahydropyrane, dioxolane, for example 1 ,3-dioxolane, dioxane, for example 1 ,4-dioxan, piperidine, pyrrolidin, imidazolidine, triazolidine, hexahydropyrimidine, piperazine, tetrahydropyridazine, triazinane, for example, 1 ,3,5-triazinane, 1 ,2,3-triazinane or 1 ,2, 4-triazinane, tetrahydrothiophene, tetrahydrothiopyrane, dithiolane, for example 1 ,3-dithiolane, dithiane, thiazolidine, oxazolidine, oxathiolane, for example 1 ,3-oxathiolane, morpholine or thio
  • the aryl radicals are chosen from phenyl, 1-naphthyl, 2-naphthyl and indenyl.
  • Aryl radicals may be unsubstituted or be substituted one or more times, for example once, twice or three times, by identical or different radicals. If a aryl radical is substituted, it preferably has one, Two or three identical or different substituents. This likewise applies to substituted aryl radicals in groups such as, for example, arylalkyl or aryloxy.
  • Aryl radicals may be condensed to a cycloalkyl or heterocycle radical, for example to form 2,3-Dihydro-benzo[1 ,4]dioxine, Benzo[1 ,3]dioxole or indane.
  • Heteroaryl radicals are monocyclic or bicyclic aromatic 5, 6, 7, 8, 9 or 10-membered ring compounds in which one or more ring atoms are oxygen atoms, sulfur atoms or nitrogen atoms, e.g. 1 , 2 or 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms or a combination of various heteroatoms.
  • the heteroaryl radicals may be attached by all positions, for example by the 1 position, 2 position, 3 position, 4 position, 5 position, 6 position, 7 position or 8 position.
  • Heteroaryl radicals may be unsubstituted or substituted one or more times, for example once, twice or three times, by identical or different radicals.
  • heteroaryl radicals such as, for example, in the radical heteroarylalkyl.
  • Aryl radicals may be condensed to a cycloalkyl or heterocycle radical.
  • heteroaryl are furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, triazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrazolyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, , benzotriazolyl, benzoxadiazolyl, benzothiadia
  • heteroaromatic radicals are furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, triazolyl, oxadiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzthiophenyl, quinolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzotriazolyl, benzoxadiazolyl.
  • variable e. g. aryl, R1
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • the invention further relates to the following processes for preparing the compounds of the formula I.
  • Z is OH or L, wherein L is a leaving group, which can undergo nucleophilic substitution with an amine, and R' is alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms.
  • the procedure for preparing the compounds of the formula I is initially a coupling of an amino compound of formula IV with an acid of formula III for preparing the compound of formula V generally in the presence of an coupling agent, for example EDC, DIC or HATU and optionally an additional base, for example triethylamine or H ⁇ nig's base, can be used in an appropriate solvent, in particular in an aprotic polar solvent such as, for example, DMF.
  • an coupling agent for example EDC, DIC or HATU
  • an additional base for example triethylamine or H ⁇ nig's base
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from -20°C to 80°, more preferably from 0°C to 20 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h depending on the composition of the mixture and the chosen temperature range.
  • L is a leaving group which can undergo nucleophilic substitution, for example Cl, Br, I or OTos.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from 20°C to 150°.
  • the reaction time is generally from 2 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from 0°C to 80°, more preferably from 0°C to 25 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the cleavage of the ester of formula Vl to the acid of formula Ia in can be achieved in a manner known by the person skilled in the art, for example by the use of a base, like aqueous sodium hydroxide or lithium hydroxide in case of primary or secondary alkyl esters, or for example by the use of an acid, like trifluoroacetic acid in case of tertiary alkyl esters.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from 0°C to 160°C.
  • the reaction time is generally from 2 min to 6 days, preferably from 2 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the optional derivatisation of the compounds of the formulae Vl or Ia to compounds of formula I 1 in which D is not defined as C(O)OH can be carried out in analogy to the processes which are described in the literature and are known to those skilled in the art, for example by reaction of compounds of formula Ia with oxalyl chloride followed by the reaction with a sulfonamide in the presence of a suitable base like sodium hydride.
  • R is -(CR11 R12)-A, wherein R11, R12 and A are defined as in formula I and B is -O-(CR11 R12)-,
  • Z is OH or L, wherein L is a leaving group, which can undergo nucleophilic substitution with an amine,
  • R' is alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms
  • R" is alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms or aryl.
  • L is a leaving group which can undergo nucleophilic substitution, for example Cl, Br, I or OTos.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from 20°C to 150°.
  • the reaction time is generally from 2 min to 6 days, preferably from 15 min to 16 h depending on the composition of the mixture and the chosen temperature range
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from 0°C to 80°, more preferably from O°C to 25 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the subsequent cleavage of the ester of formula VIII to the acid of formula IX can be achieved in a manner known by the person skilled in the art, for example by the use of a base, like aqueous sodium hydroxide or lithium hydroxide, for example in case of primary or secondary alkyl esters, or by the use of an acid, like trifluoroacetic acid, for example in case of tertiary alkyl esters.
  • the reaction temperature in this case is generally from -30°C to 200°C 1 preferably from 0°C to 160°C.
  • the reaction time is generally from 2 min to 6 days, preferably from 2 min to 16 h.
  • the resulting compound of formula IX can be coupled with the amino compound of formula IV to form the compound of formula Vl generally in the presence of an coupling agent, for example EDC, DIC or HATU and optionally an additional base, for example triethylamine or H ⁇ nig's base, in an appropriate solvent, in particular in an aprotic polar solvents such as, for example, DMF.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from -20°C to 80°, more preferably from 0°C to 20 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the optional cleavage of the ester of formula Vl to the acid of formula Ia in can be achieved as mentioned above, for example by the use of a base, like aqueous sodium hydroxide or lithium hydroxide, for example in case of primary or secondary alkyl esters, or by the use of an acid, like trifluoroacetic acid, for example in case of tertiary alkyl esters.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from O°C to 160.
  • the reaction time is generally from 2 min to 6 days, preferably from 2min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the optional derivatisation of the compounds of the formulae Vl or Ia to compounds of formula I 1 in which D is not defined as C(O)OH can be carried out in analogy to the processes which are described in the literature and are known to those skilled in the art, for example by reaction of compounds of formula Ia with oxalyl chloride followed by the reaction with a sulfonamide in the presence of a suitable base like sodium hydride.
  • V-R is HC ⁇ C-A and R is -C ⁇ C-A
  • V-R is (R'"O) 2
  • V-R is HNR17-C(R18R19)-A and R is -NR17-C(R18R19)-A
  • V-R is HNR20-C(O)-A and R is -NR20-C(O)-A, wherein R17, R18, R19, R20, R52, R53 and
  • W is halogen, for example I 1 Br or Cl, or triflate, mesylate or tosylate,
  • R' is alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms
  • R'" is H or alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, or alternatively both R'" form, together with the oxygen atoms they are attached to and with the boron atom the oxygen atoms are attached to, a five, six or seven membered ring, which can be unsubstituted or substituted by 1 , 2, 3, 4, 5, 6, 7 or 8 alkyl groups, R"" is alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, Hal is halogen, for example I, Br or Cl.
  • the procedure for preparing the compounds of the formula I is initially a coupling of an amino compound of formula IV with an acid of formula X for preparing the compound of formula Xl generally in the presence of an coupling agent, for example EDC, DIC or HATU and optionally an additional base, for example thethylamine or H ⁇ nig's base, can be used in an appropriate solvent, in particular in an aprotic polar solvent such as, for example, DMF.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from -20°C to 80°, more preferably from O°C to 20 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h depending on the composition of the mixture and the chosen temperature range.
  • a compound of formula V can be converted into a compound of formula
  • XI in which W is defined as triflate, tosylate or mesylate, by reacting it with an anhydride or chloride of trifluoromethane sulfonic acid para-toluene sulfonic acid or methyl sulfonic acid in the presence of a suitable base, for example triethylamine in an appropriate solvent, for example dichloromethane.
  • the reaction temperature in this case is generally from -80°C to 200°C, preferably from -20°C to 80°, more preferably from O°C to 20 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h depending on the composition of the mixture and the chosen temperature range.
  • the transformation of the compound of formula Xl to the compound of formula XII can be achieved by reacting with a reagent V-R, often under inert conditions and in an appropriate solvent, in the presence of a suitable catalytic system, which can contain a palladium and/or copper complex and/or salt, for example
  • Pd2dba3, Pd(Ph3)4, Pd(OAc)2 or CuI optionally additional ligands as, for example, phosphine, amine or carbene ligands, and optionally auxiliaries like amines, pyridine, quaternary ammonium salts, CsF, Ag2CO3, Na2CO3, K2CO3, CS2CO3, NaOtBu,
  • the reaction temperature in this case is generally from -30°C to 250°C, preferably from 0°C to 250°, more preferably from 20°C to 200 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the cleavage of the ester of formula XII to the acid of formula Ib can be achieved in a manner known by the person skilled in the art, for example by the use of a base, like aqueous sodium hydroxide or lithium hydroxide in case of primary or secondary alkyl esters, or for example by the use of an acid, like trifluoroacetic acid in case of tertiary alkyl esters.
  • the reaction temperature in this case is generally from -3O°C to 200°C, preferably from 0°C to 16O°C.
  • the reaction time is generally from 2 min to 6 days, preferably from 2 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • One optional derivatisation of the compounds of the formulae XII or Ib to compounds of formula I, in which D is not defined as C(O)OH, can be carried out in analogy to the processes which are described in the literature and are known to those skilled in the art, for example by reaction of compounds of formula Ib with oxalyl chloride followed by the reaction with a sulfonamide in the presence of a suitable base like sodium hydride.
  • Scheme 4 which comprises a) reacting a compound of formula XIII with a reagent V-R to a compound of formula XIV b) converting an ester of formula XIV to an acid of formula XV or, alternatively, reacting a compound of formula X with a reagent V-R to a compound of formula XV c) coupling of an acid of formula XV with an amino compound of formula IV to an amide of formula XII d) converting an ester of formula XII to an acid of formula Ib and optionally converting an acid of formula Ib to a compound of formula I or, alternatively, converting an ester of formula XII to a compound of formula I; wherein in the compounds of the formulae Ib, IV, X, XII, XIII, XIV and XV X, Y1 to Y4, R1 and R2 are defined as in formula I, V-R is HC ⁇ C-A and R is -C ⁇ C
  • R'" is H or alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, or alternatively both R'" form, together with the oxygen atoms they are attached to and with the boron atom the oxygen atoms are attached to, a five, six or seven membered ring, which can be unsubstituted or substituted by 1 , 2, 3, 4, 5, 6, 7 or 8 alkyl groups, R"" is alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, Hal is halogen, for example I, Br or Cl.
  • the procedure for preparing the compounds of the formula I is initially a transformation of the compound of formula XIII to the compound of formula XIV which can be achieved by reacting with a reagent V-R, often under inert conditions and in an appropriate solvent, in the presence of a suitable catalytic system, which can contain a palladium and/or copper complex and/or salt, for example Pd2dba3, Pd(Phi3)4,
  • Pd(OAc)2 or CuI 1 optionally additional ligands as, for example, phosphine, amine or carbene ligands, and optionally auxiliaries like amines, pyridine, quaternary ammonium salts, CsF, Ag2CO3, Na2CC>3, K2CO3, CS2CO3, NaOtBu 1 KOtBu, NaOAc, KOAc,
  • additional ligands as, for example, phosphine, amine or carbene ligands, and optionally auxiliaries like amines, pyridine, quaternary ammonium salts, CsF, Ag2CO3, Na2CC>3, K2CO3, CS2CO3, NaOtBu 1 KOtBu, NaOAc, KOAc,
  • the reaction temperature in this case is generally from -30°C to 250°C 1 preferably from 0°C to 250°, more preferably from 2O°C to 200 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the subsequent cleavage of the ester of formula XIV to the acid of formula XV can be achieved in a manner known by the person skilled in the art, for example by the use of a base, like aqueous sodium hydroxide or lithium hydroxide, for example in case of primary or secondary alkyl esters, or by the use of an acid, like trifluoroacetic acid, for example in case of tertiary alkyl esters.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from 0°C to 160°C.
  • the reaction time is generally from 2 min to 6 days, preferably from 2 min to 16 h.
  • a transformation of a compound of formula X to the compound of formula XV can be achieved by reacting with a reagent V-R, often under inert conditions and in an appropriate solvent, in the presence of a suitable catalytic system, which can contain a palladium and/or copper complex and/or salt, for example Pd2dba3, Pd(Ph3)4, Pd(OAc)2 or CuI, optionally additional ligands as, for example, phosphine, amine or carbene ligands, and optionally auxiliaries like amines, pyridine, quaternary ammonium salts, CsF, Ag2CO3, Na2CO3, K2CO3, CS2CO3, NaOtBu, KOtBu, NaOAc,
  • a suitable catalytic system which can contain a palladium and/or copper complex and/or salt, for example Pd2dba3, Pd(Ph3)4, Pd(OAc)2 or CuI, optionally additional ligands as
  • the reaction temperature in this case is generally from -3O°C to 250°C, preferably from 0°C to 250°, more preferably from 20°C to 200 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the resulting compound of formula XV can be coupled with the amino compound of formula IV to form the compound of formula XII generally in the presence of a coupling agent, for example EDC, DIC or HATU and optionally an additional base, for example triethylamine or H ⁇ nig's base, in an appropriate solvent, in particular in aprotic polar solvents such as, for example, DMF.
  • a coupling agent for example EDC, DIC or HATU and optionally an additional base, for example triethylamine or H ⁇ nig's base
  • an appropriate solvent in particular in aprotic polar solvents such as, for example, DMF.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from -20°C to 80°, more preferably from O°C to 20 °C.
  • the reaction time is generally from 15 min to 6 days, preferably from 15 min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the cleavage of the ester of formula XII to the acid of formula Ib in can be achieved as mentioned above, for example by the use of a base, like aqueous sodium hydroxide or lithium hydroxide, for example in case of primary or secondary alkyl esters, or by the use of an acid, like trifluoroacetic acid, for example in case of tertiary alkyl esters.
  • the reaction temperature in this case is generally from -30°C to 200°C, preferably from 0°C to 160.
  • the reaction time is generally from 2 min to 6 days, preferably from 2min to 16 h, depending on the composition of the mixture and the chosen temperature range.
  • the compounds of formula Ia and Ib are contained in the compound of formula I.
  • the starting compounds of the formulae III, IV, V, VII, X and XIII are commercially available or can be prepared by a skilled artisan according to procedures described in the literature.
  • the workup and optionally the purification of the products and/or intermediates are effected by the customary methods such as extraction, chromatography or crystallization and the customary dryings.
  • Functional groups in the starting compounds may be present in protected form or in the form of precursors, and then be converted into the desired groups in the compounds of the formula I prepared by the process described above.
  • Corresponding protective group techniques are known to the skilled worker.
  • Another aspect of the invention is the use of a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of chemokine mediated diseases.
  • the invention further relates to the use of a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of a chemokine mediated disease, wherein the chemokine binds to a CXC receptor.
  • Another aspect of the invention is the use of a compound of the formula I and/or the pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of a chemokine mediated disease, wherein the chemokine binds to a CXCR2 and/or CXCR1 receptor, in particular to a CXCR2 receptor.
  • the invention further relates to the use of a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of rheumatoid arthritis, chronic obstructive pulmonary disease, adult or acute respiratory distress syndrome, asthma, atherosclerosis, myocardial and renal ischemia/reperfusion injury, peripheral limb ischemia/reperfusion injury, inflammatory bowel disease, ulcerative colitis, Crohn's disease, meconium apriration syndrome, atopic dermatitis, cystic fibrosis, psoriasis, psoriatic arthritis, multiple sclerosis, angiogenesis, restenosis, osteoarthritis, osteoporosis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, glomerulonephritis, thrombosis, graft vs.
  • the invention further relates to the use of a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemia/reperfusion injuries, chronic obstructive pulmonary disease, asthma, and rheumatoid arthritis, chemokine (such as, but not limited to IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , NAP-2, ENA-78, or GCP-2) mediated diseases which include adult respiratory distress syndrome, inflammatory bowel disease, ulcerative colitis, Crohn's disease, atopic dermatitis, cystic fibrosis, psoriasis, dermatitis, multiple sclerosis, angiogenesis, restenosis, osteoarthritis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, glomerulone
  • a further aspect of the present invention is the use of a compound of the formula Il
  • R3, R4, R5 and R6 are, independently of one another, hydrogen, F, Cl, Br, I, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, cycloalkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 hydrogen atoms may be substituted by fluorine atoms, alkoxy having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, -S-alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, OH, CN, NO2,
  • R28 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms, aryl, C(O)H, C(O)alkyl with alkyl having 1 , 2, 3 or 4 carbon atoms or C(O)aryl;
  • R29 is hydrogen, OH, alkyl with 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl;
  • R30, R31 , R33 and R34 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R32 is OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl;
  • 0 and p are, independently of one another, 1 or 2;
  • R7 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or C(O)R35;
  • R35 is hydrogen, alkyl with 1 , 2, 3 or 4 carbon atoms or aryl;
  • Y1. Y2, Y3 and Y4 are, independently of one another, -CR8- or Nitrogen, with the proviso that at least two of Y1 , Y2, Y3 and Y4 are defined as -CR8-;
  • R8 is hydrogen, F, Cl 1 Br, I, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, cycloalkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 hydrogen atoms may be substituted by fluorine atoms, alkoxy having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, -S-alkyl having 1 , 2, 3, 4, 5
  • R36 is hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms
  • R37 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms, aryl, C(O)H, C(O)alkyl with alkyl having 1 , 2, 3 or 4 carbon atoms or C(O)aryl
  • R38 is hydrogen, OH, alkyl with 1 ,2,3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl
  • R39, R40, R42 and R43 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl
  • R41 is OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl
  • q and r are, independently of one another, 1 or 2; is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, heterocycle,
  • -heteroaryl in which the aryl and heteroaryl radicals can be substituted by F, Cl, Br, I, alkoxy having 1 , 2, 3 or 4 carbon atoms, alkyl having 1, 2, 3 or 4 carbon atoms or O a -(CH2)tr(CF2) c -CF3 ;
  • R9 is hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms
  • R10 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms, aryl
  • R44 is hydrogen, OH, alkyl with 1 ,2,3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms or aryl;
  • R45, R46, R48 and R49 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R47 is OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms or aryl; a is zero or 1 ; b, c, k and I are, independently of one another, zero, 1 , 2 or 3; s and t are, independently of one another, 1 or 2; in which the aryl or heteroaryl radical can be condensed to an cycloalkyl or heterocycle radical and in which the aryl or heteroaryl radical and the optionally condensed cycloalkyl or heterocycle radical are unsubstituted or substituted by 1 , 2, 3 or 4 radicals selected from the group consisting of F, Cl, Br, I, OH, CN, NO2, SF5, alkyl having 1 , 2, 3, 4, 5 or 6 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 or 13 hydrogen atoms may be substituted by fluorine atoms, cycloalky
  • -heteroaryl in which the aryl and heteroaryl radicals can be substituted by F 1 Cl, Br, I, alkoxy having 1 , 2, 3 or 4 carbon atoms, alkyl having 1 , 2, 3 or 4 carbon atoms or O a -(CH2)tr(CF2)c-CF3 ;
  • R9 is hydrogen or alkyl having 1 , 2, 3 or 4 carbon atoms
  • R10 is hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms, aryl, C(O)H, C(O)alkyl having 1 , 2, 3 or 4 carbon atoms or C(O)aryl
  • R44 is hydrogen, OH, alkyl with 1 ,2,3 or 4 carbon atoms, alkoxy with 1 , 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms or aryl
  • R45, R46, R48 and R49 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R47 is OH, alkyl having 1 , 2, 3 or 4 carbon atoms, alkoxy with 1 ,
  • a is zero or 1 ;
  • b, c, k and I are, independently of one another, zero, 1 , 2 or 3;
  • s and t are, independently of one another, 1 or 2;
  • R11 , R12, R13, R14, R15, R16, R17, R18, R19, R20, R50, R51 , R52, R53, R54, R55, R56 and R57 are, independently of one another, hydrogen or alky! having 1 , 2, 3 or 4 carbon atoms, in which 1 , 2, 3, 4, 5, 6, 7, 8 or 9 hydrogen atoms may be substituted by fluorine atoms;
  • R21 and R22 are, independently of one another, hydrogen, -SO2-alkyl having 1 ,
  • R23 is alkyl having 1 ,2,3 or 4 carbon atoms or aryl
  • R24 and R25 are, independently of one another, hydrogen, alkyl having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R58 is hydrogen, OH, CN, alkyl having 1 , 2, 3 or 4 carbon atoms or alkoxy having 1 , 2, 3 or 4 carbon atoms or aryl;
  • R1 and R2 form, together with the carbon atom to which they are attached, a 3-, A-, 5- or 6- membered carbon ring, in which the formed carbon ring can be condensed to an aryl or heteroaryl radical; wherein the formed carbon ring and the condensed aryl or heteroaryl radical can be unsubstituted or substituted by 1 , 2 or 3 radicals selected form the group consisting of F, Cl, Br, I or alkyl having 1 , 2, 3 or 4 carbon atoms; and/or pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients for producing a medicament for the treatment or prophylaxis of chemokine mediated diseases.
  • the invention further relates to the use of a compound of the formula Il and/or a pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of a chemokine mediated disease, wherein the chemokine binds to a CXC receptor, for example wherein the chemokine binds to a CXCR2 and/or CXCR1 receptor, in particular to a CXCR2 receptor.
  • Another aspect of the invention is the use of a compound of the formula Il and/or a pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of arthritis, chronic obstructive pulmonary disease, adult or acute respiratory distress syndrome, asthma, atherosclerosis, myocardial and renal ischemia/reperfusion injury, peripheral limb ischemia/reperfusion injury, inflammatory bowel disease, ulcerative colitis, Crohn's disease, meconium apriration syndrome, atopic dermatitis, cystic fibrosis, psoriasis, psoriatic arthritis, multiple sclerosis, angiogenesis, restenosis, osteoarthritis, osteoporosis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, glomerulonephritis, thrombosis, graft vs.
  • the invention further relates to the use of a compound of the formula Il and/or a pharmaceutically acceptable salt and/or a prodrug thereof alone or in combination with other medicaments or active ingredients as for producing a medicament for the treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemia/reperfusion injuries, chronic obstructive pulmonary disease, asthma, and rheumatoid arthritis, chemokine (such as, but not limited to IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , NAP-2, ENA-78, or GCP-2) mediated diseases which include adult respiratory distress syndrome, inflammatory bowel disease, ulcerative colitis, Crohn's disease, atopic dermatitis, cystic fibrosis, psoriasis, dermatitis, multiple sclerosis, angiogenesis, restenosis, osteoarthritis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, glomerulone
  • Examples no. 110, 203, 204, 238, 239, 308, 359, 360, 361 , 362, 364, 366, 370, 371 vide infra represent compounds of the formula Il in the context of the above described uses. All other example compounds exemplify compounds of the formula I.
  • certain compounds of formula I or formula Il may have utility as antagonists of the CX3CR1 receptor.
  • Such compounds are expected to be particularly useful in the treatment of disorders within the central and peripheral nervous system and other conditions characterized by an activation of microglia and/or infiltration of leukocytes (e.g. stroke/ischemia and head trauma).
  • a medicine or pharmaceutical composition for human or veterinary use comprising an effective amount of a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof, together with pharmaceutically acceptable carriers and additives, alone or in combination with other active pharmaceutical ingredients or medicaments.
  • Medicaments which comprise a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof can in this connection be administered, for example, orally, parenterally, intravenously, rectally, transdermal ⁇ or by inhalation, the preferred administration being dependent on the particular characteristics of the disorder.
  • the compounds of the formula I may moreover be used alone or together with pharmaceutical excipients, both in veterinary medicine and in human medicine.
  • the medicaments generally comprise active ingredients of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof in an amount of from 0.01 mg to 1 g per dose unit.
  • excipients suitable for the desired pharmaceutical formulation are familiar to the skilled worker on the basis of his expert knowledge.
  • solvents, gel formers, suppository bases, tablet excipients, and other active ingredient carriers it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavorings, preservatives, solubilizers or colors.
  • the active compounds are mixed with additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable dosage forms such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions.
  • suitable dosage forms such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily solutions.
  • inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. It is moreover possible for the preparation to take place both as dry granules and as wet granules.
  • suitable oily carriers or solvents are vegetable or animal oils such as sunflower oil or fish liver oil.
  • the active compounds used are converted, if desired with the substances customary for this purpose, such as solubilizers, emulsifiers or other excipients, into a solution, suspension or emulsion.
  • suitable solvents are: water, physiological saline or alcohols, e.g. ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
  • Suitable as pharmaceutical formulation for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredient of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof in a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents.
  • the formulation may, if required, also contain other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas.
  • Such a preparation normally contains the active ingredient in a concentration of about 0.1 to 10, in particular of about 0.3 to 3% by weight.
  • the dosage of the active ingredient of the formula I to be administered, and the frequency of administration, depend on the potency and duration of action of the compounds used; additionally also on the nature and severity of the disorder to be treated and on the sex, age, weight and individual responsiveness of the mammal to be treated.
  • the daily dose of a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof for a patient weighing about 75 kg is at least 0.001 mg/kg, preferably 0.01 mg/kg, to a maximum of 50 mg/kg, preferably 1 mg/kg, of body weight.
  • a compound of the formula I and/or a pharmaceutically acceptable salt and/or a prodrug thereof for a patient weighing about 75 kg is at least 0.001 mg/kg, preferably 0.01 mg/kg, to a maximum of 50 mg/kg, preferably 1 mg/kg, of body weight.
  • higher and, in particular, more frequent dosages may also be necessary, e.g. up to 4 single doses a day.
  • Up to 700 mg a day may be necessary, in particular on i.v. administration, for example for a patient with infarction in the intensive care unit, and the compounds of the invention can be administered by infusion.
  • Example 144 i- ⁇ -Trifluoromethyl-pyridin-3-ylmethoxy)-naphthalene-2-carboxylic acid (2-methylsulfonylamino-1 ,1-dimethyl-2-oxo-ethyl)-amide
  • Example 148 2- ⁇ [1-(5-Chloro-6-methoxy-pyridin-3-ylmethoxy)-naphthalene-2- carbonyl]-amino ⁇ -2-methyl-propionic acid
  • Example 150 2-( ⁇ 1-[6-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethoxy]-naphtha-lene-2- carbonyl ⁇ -amino ⁇ -2-methyl-propionic acid
  • Example 151 2-Methyl-2-( ⁇ 1-[6-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethoxy]-naphtha- lene-2-carbonyl ⁇ -amino)-butyric acid
  • Example 152 2- ⁇ [1-(6-Methoxy-pyridin-3-ylmethoxy)-naphthalene-2-carbonyl]-amino ⁇ - 2-methyl-propionic acid
  • Example 153 2- ⁇ [1 -(6-Methoxy-pyridin-3-ylmethoxy)-naphthalene-2-carbonyl]-amino ⁇ - 2-methyl-butyric acid
  • Example 154 2- ⁇ [1-(1-Benzothiazol-2-yl-ethoxy)-naphthalene-2-carbonyl]-amino ⁇ -2- methyl-propionic acid
  • Example 155 1-(6-Trifluoromethyl-pyridin-3-ylmethoxy)-naphthalene-2-carboxylic acid [1 -(N-hydroxycarbamimidoyl)-i -methyl-ethyl]-amide
  • Examples 156 and 157 2- ⁇ [1-(4-Dimethylamino-2-trifluoromethyl-quinolin-6- ylmethoxy)-naphthalene-2-carbonyl]-amino ⁇ -2-methyl-propionic acid and 2- ⁇ [1-(4- methoxy-2-trifluoromethyl-quinolin-6-ylmethoxy)-naphthalene-2-carbonyl]-amino ⁇ -2- methyl-propionic acid
  • Example 159 2- ⁇ [5-Fluoro-3-(6-trifluoromethyl-pyridin-3-ylmethoxy)-benzo[b]thio- phene-2-carbonyl]-amino ⁇ -2-methyl-propionic acid
  • Example 163 4-[2-(1-Carboxy-1-methyl-propylcarbamoyl)-4-chloro-naphthalen-1- yloxymethyl]-piperidine-1-carboxylic acid tert-butyl ester
  • Example 165 2-( ⁇ 4-Chloro-1-[1-(2,2,2-trifluoro-acetyl)-piperidin-4-yl-methoxy]- naphthalene-2-carbonyl ⁇ -amino ⁇ -2-methyl-butyric acid
  • Trifluoroacetic anhydride (0.018 mL) was added to 2- ⁇ [4-chloro-1-(piperidin-4-yl- methoxy)-naphthalene-2-carbonyl]-amino ⁇ -2-methyl-butyric acid (see example 164, 0.050 g) at 0 °C with vigorous stirring. The mixture was stirred at 0 °C for 5 min. and a further portion of trifluoroacetic anhydride (0.003 mL) was then added. The mixture was stirred at 85 °C for 1.5 hour, then diluted with 1 M HCI and extracted with diethyl ether. The organic phase was washed with brine, dried over sodium sulphate and concentrated in vacuo.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
PCT/EP2005/013624 2004-12-30 2005-12-17 Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation Ceased WO2006069656A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA002592430A CA2592430A1 (en) 2004-12-30 2005-12-17 Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation
BRPI0519452-0A BRPI0519452A2 (pt) 2004-12-30 2005-12-17 inibidores de cxcr2
NZ556192A NZ556192A (en) 2004-12-30 2005-12-17 Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation
JP2007548720A JP5123667B2 (ja) 2004-12-30 2005-12-17 炎症の治療においてｃｘｃｒ２阻害剤として使用される縮合二環式カルボキサミド誘導体
MX2007007068A MX2007007068A (es) 2004-12-30 2005-12-17 Derivados de carboxamida biciclicos condensados para uso como inhibidores de cxcr2 en el tratamiento de la inflamacion.
AU2005321609A AU2005321609B2 (en) 2004-12-30 2005-12-17 Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation
EP05818685A EP1836158B1 (en) 2004-12-30 2005-12-17 Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation
AT05818685T ATE543795T1 (de) 2004-12-30 2005-12-17 Kondensierte bicyclische carbonsäureamidderivate zur verwendung als cxcr2-inhibitoren bei der behandlung von entzündungen
IL184173A IL184173A (en) 2004-12-30 2007-06-24 Fused bicyclic carboxamide derivatives and uses thereof in the preparation of medicaments for the treatment or prophylaxis of chemokine mediated diseases and of acute and chronic inflammatory diseases
US11/771,958 US7919628B2 (en) 2004-12-30 2007-06-29 CXCR2 inhibitors
NO20073932A NO20073932L (no) 2004-12-30 2007-07-26 Fuserte bicykliske karboksamidderivater for anvendelse som CXCR2 inhibitorer i behandlingen av inflammasjon
US13/079,522 US8283479B2 (en) 2004-12-30 2011-04-04 CXCR2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04031009A EP1676834A1 (en) 2004-12-30 2004-12-30 Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
EP04031009.6 2004-12-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/771,958 Continuation US7919628B2 (en) 2004-12-30 2007-06-29 CXCR2 inhibitors

Publications (1)

Publication Number Publication Date
WO2006069656A1 true WO2006069656A1 (en) 2006-07-06

Family

ID=34928051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/013624 Ceased WO2006069656A1 (en) 2004-12-30 2005-12-17 Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation

Country Status (21)

Country Link
US (2) US7919628B2 (enExample)
EP (2) EP1676834A1 (enExample)
JP (1) JP5123667B2 (enExample)
KR (1) KR20070091634A (enExample)
CN (1) CN101094830A (enExample)
AR (1) AR055830A1 (enExample)
AT (1) ATE543795T1 (enExample)
AU (1) AU2005321609B2 (enExample)
BR (1) BRPI0519452A2 (enExample)
CA (1) CA2592430A1 (enExample)
IL (1) IL184173A (enExample)
MA (1) MA29113B1 (enExample)
MX (1) MX2007007068A (enExample)
NO (1) NO20073932L (enExample)
NZ (1) NZ556192A (enExample)
PE (1) PE20060855A1 (enExample)
RU (1) RU2404962C2 (enExample)
TW (1) TW200639141A (enExample)
UY (1) UY29322A1 (enExample)
WO (1) WO2006069656A1 (enExample)
ZA (1) ZA200704089B (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510268A (ja) * 2006-11-23 2010-04-02 ノバルティス アーゲー Ｃｘｃｒ２アンタゴニストとしての５−スルファニルメチル−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−オール
JP2010511608A (ja) * 2006-11-30 2010-04-15 ダウ アグロサイエンシィズ エルエルシー ２−置換−５−（１−アルキルチオ）アルキルピリミジンの製造方法
JP2010530847A (ja) * 2007-06-05 2010-09-16 サノフィ−アベンティス 置換されたベンゾイルアミノ−インダン−２−カルボン酸及び関連化合物
CN105906608A (zh) * 2016-05-03 2016-08-31 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
CN106187974A (zh) * 2016-07-01 2016-12-07 广州军区广州总医院 具有抗肿瘤作用的鱼藤素断环结构与氨基酸衍生物的合成方法
US9919060B2 (en) 2009-05-01 2018-03-20 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
WO2019219820A1 (en) * 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
WO2021113808A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Cftr-modulating arylamides
US11739328B2 (en) 2017-12-01 2023-08-29 The Texas A&M University System Angleman syndrome antisense treatment
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
US12415785B2 (en) 2019-12-18 2025-09-16 Ctxt Pty Ltd Compound modulators of sting

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
RU2457204C2 (ru) 2006-01-27 2012-07-27 Файброджен, Инк. Цианоизохинолиновые соединения (варианты), фармацевтическая композиция на их основе, способ ингибирования активности гидроксилазы гипоксия-индуцибельного фактора (hif) и способ лечения и/или профилактики состояния, связанного с hif, и/или состояния, связанного с эритропоэтином, и/или анемии
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
AU2007264114A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New CXCR2 inhibitors
EP2041072B1 (en) 2006-06-28 2013-09-11 Sanofi Cxcr2 antagonists
JP5352455B2 (ja) 2006-06-30 2013-11-27 サノフイ Ｃｘｃｒ２阻害剤
CA2669579A1 (en) * 2006-11-23 2008-05-29 Novartis Ag 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
AU2013203591B2 (en) * 2009-05-01 2017-01-19 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
WO2012079154A1 (en) * 2010-12-14 2012-06-21 Dalhousie University Selective estrogen receptor modulators
CN104395301B (zh) * 2012-06-19 2017-07-28 霍夫曼-拉罗奇有限公司 双环噻吩基酰胺化合物
CN104619705B (zh) * 2012-09-12 2018-01-02 霍夫曼-拉罗奇有限公司 作为脂肪酸结合蛋白(fabp)4和/或5的抑制剂的非成环噻吩基酰胺
WO2014114603A1 (en) * 2013-01-24 2014-07-31 F. Hoffmann-La Roche Ag Substituted thiazole compounds
DK2951159T3 (en) 2013-01-24 2018-11-19 Fibrogen Inc CRYSTALLIC FORMS OF {[1-CYANO-5- (4-CHLORPHENOXY) -4-HYDROXY-ISOQUINOLIN-3-CARBONYL] -AMINO} ACETIC ACID
CA2977839C (en) * 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
RS62140B1 (sr) * 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
CN106660950A (zh) * 2014-07-31 2017-05-10 葛兰素史密斯克莱知识产权发展有限公司 Cxcr2拮抗剂用于预防和/或治疗化疗诱导的周围神经病变(cipn)的用途
WO2020014068A1 (en) 2018-07-09 2020-01-16 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic heterocyclic compounds
CA3133100A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
WO2021113806A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
AU2021278889A1 (en) 2020-05-29 2023-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anthelmintic heterocyclic compounds
CN111559991B (zh) * 2020-06-01 2022-01-25 河南省锐达医药科技有限公司 一种萘胺类化合物及其盐的制备方法和应用
UY39995A (es) 2021-11-01 2023-05-15 Boehringer Ingelheim Vetmedica GmbH Compuestos de pirrolopiridazina como antihelmínticos
CN115385865B (zh) * 2022-06-29 2023-06-16 深圳大学 一种具有cxcr2抑制活性的小分子抑制剂及其制备方法与应用
CN116041300B (zh) * 2023-02-20 2024-04-26 沈阳药科大学 一种2,2-二甲基苯并吡喃类衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007351A2 (en) * 1997-08-07 1999-02-18 Zeneca Limited Indole derivatives and their use as mcp-1 antagonists
US20020123522A1 (en) * 1996-09-12 2002-09-05 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962224A (en) 1987-12-23 1990-10-09 American Home Products Corporation N-naphthoylglycines as aldose reductase inhibitors
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
IT1317826B1 (it) 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
US6673791B2 (en) * 2001-07-30 2004-01-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB2389580A (en) * 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
CN102718708A (zh) * 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
CA2572750A1 (en) 2003-09-10 2005-03-17 Anil Koul Heterobicyclic compounds as pharmaceutically active agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
DE602004008505T2 (de) 2003-11-20 2008-05-21 Eli Lilly And Co., Indianapolis Modulatoren des vitamin-d-rezeptors
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2006040646A1 (en) 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
JP2008519761A (ja) 2004-11-09 2008-06-12 スミスクライン ビーチャム コーポレーション グリコーゲンホスホリラーゼ阻害化合物およびその医薬組成物
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
AR055319A1 (es) 2005-03-17 2007-08-15 Wyeth Corp Derivados de isoquinoleina, composiciones farmaceuticas y usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123522A1 (en) * 1996-09-12 2002-09-05 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
WO1999007351A2 (en) * 1997-08-07 1999-02-18 Zeneca Limited Indole derivatives and their use as mcp-1 antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs", 1985, ELSEVIER
BOSCHELLI D H ET AL: "Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo[b]thiophene-, Benzofuran-, Indole-, and Naphthalene-2-carboxamides: Identification of PD 144795 as an Antiinflammatory Agent", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, 1995, pages 4597 - 4614, XP002286757, ISSN: 0022-2623 *
FLEISHER ET AL., ADVANCED DRUG DELIVERY REVIEWS, vol. 19, 1996, pages 115 - 130
H. BUNDGAARD, DRUGS OF THE FUTURE, vol. 16, 1991, pages 443

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510268A (ja) * 2006-11-23 2010-04-02 ノバルティス アーゲー Ｃｘｃｒ２アンタゴニストとしての５−スルファニルメチル−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−オール
JP2010511608A (ja) * 2006-11-30 2010-04-15 ダウ アグロサイエンシィズ エルエルシー ２−置換−５−（１−アルキルチオ）アルキルピリミジンの製造方法
JP2013056912A (ja) * 2006-11-30 2013-03-28 Dow Agrosciences Llc ２−置換−５−（１−アルキルチオ）アルキルピリミジンの製造方法
JP2010530847A (ja) * 2007-06-05 2010-09-16 サノフィ−アベンティス 置換されたベンゾイルアミノ−インダン−２−カルボン酸及び関連化合物
US9919060B2 (en) 2009-05-01 2018-03-20 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
CN105906608A (zh) * 2016-05-03 2016-08-31 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
CN106187974A (zh) * 2016-07-01 2016-12-07 广州军区广州总医院 具有抗肿瘤作用的鱼藤素断环结构与氨基酸衍生物的合成方法
US11739328B2 (en) 2017-12-01 2023-08-29 The Texas A&M University System Angleman syndrome antisense treatment
US11760773B2 (en) 2018-02-02 2023-09-19 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
WO2019219820A1 (en) * 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
US11613525B2 (en) 2018-05-16 2023-03-28 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
AU2019270394B2 (en) * 2018-05-16 2024-07-11 Ctxt Pty Ltd Substituted condensed thiophenes as modulators of STING
WO2021113808A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Cftr-modulating arylamides
US12415785B2 (en) 2019-12-18 2025-09-16 Ctxt Pty Ltd Compound modulators of sting

Also Published As

Publication number Publication date
RU2404962C2 (ru) 2010-11-27
US7919628B2 (en) 2011-04-05
CN101094830A (zh) 2007-12-26
AU2005321609A1 (en) 2006-07-06
AR055830A1 (es) 2007-09-12
UY29322A1 (es) 2006-07-31
AU2005321609B2 (en) 2011-02-17
MX2007007068A (es) 2007-08-08
EP1836158A1 (en) 2007-09-26
KR20070091634A (ko) 2007-09-11
RU2007128949A (ru) 2009-02-10
CA2592430A1 (en) 2006-07-06
TW200639141A (en) 2006-11-16
EP1676834A1 (en) 2006-07-05
IL184173A (en) 2011-10-31
US20080090854A1 (en) 2008-04-17
ATE543795T1 (de) 2012-02-15
US20110184177A1 (en) 2011-07-28
ZA200704089B (en) 2008-09-25
PE20060855A1 (es) 2006-10-10
US8283479B2 (en) 2012-10-09
JP5123667B2 (ja) 2013-01-23
EP1836158B1 (en) 2012-02-01
IL184173A0 (en) 2007-10-31
NO20073932L (no) 2007-08-09
NZ556192A (en) 2010-06-25
BRPI0519452A2 (pt) 2009-01-27
MA29113B1 (fr) 2007-12-03
JP2008526695A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
EP1836158B1 (en) Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation
US8642643B2 (en) CXCR2 antagonists
KR101762574B1 (ko) 플라즈미노겐 액티베이터 인히비터-1 저해제
WO2008000409A1 (en) New cxcr2 inhibitors
EP1049662A1 (en) Inhibitors of alpha4 mediated cell adhesion
ZA200601559B (en) Compounds for inflammation and immune-related uses
US20060223868A1 (en) Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1)
US8552033B2 (en) Inhibitors of CXCR2
CN1732163B (zh) 作为抗炎和免疫调节及抗增殖试剂的芳香化合物
KR20150038218A (ko) 당뇨병 치료에 유용한 티오펜 유도체들
ES2377661T3 (es) Nuevos compuestos III
MX2007007433A (es) Nuevos derivados de ciclohexano.
CA2596613A1 (fr) Derives de n-[(4, 5-diphenyl-3 -alkyl-2-thienyl) methyl] amine (amide , thiouree et uree) comme antagonistes des recepteurs cb1 des cannabinoides
JPWO2006049232A1 (ja) チアゾール環を含むカルボン酸誘導体およびその医薬用途
WO2012130299A1 (en) Peptidase inhibitors
HK1113348A (en) Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation
WO2008000410A1 (en) Cxcr2 inhibitors
DE60124397T2 (de) Inhibitoren von serinproteasen
NL1028559C2 (nl) Verbindingen die bruikbaar zijn voor de behandeling van ziekten

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12007501083

Country of ref document: PH

WWE Wipo information: entry into national phase

Country of ref document: MX

Ref document number: MX/a/2007/007068

WWE Wipo information: entry into national phase

Ref document number: DZP2007000374

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2005818685

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 184173

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2592430

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 07065248

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 556192

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 11771958

Country of ref document: US

Ref document number: 200580045462.4

Country of ref document: CN

Ref document number: 2007548720

Country of ref document: JP

Ref document number: 2005321609

Country of ref document: AU

Ref document number: 1020077015119

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2903/CHENP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005321609

Country of ref document: AU

Date of ref document: 20051217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005321609

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007128949

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005818685

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 184173

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: 11771958

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0519452

Country of ref document: BR